Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Parker, Fei Fei Liu, Kristen Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J Keating, Sonja Sorensen, Emily Dorman

Blood (2021) 138 (Supplement 1): 3003.

https://doi.org/10.1182/blood-2021-150755

Published: 2021

Journal Articles

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Matthias Stelljes, MD, Yun Su, MD MPH, MS, Kyle Fahrbach, PhD, Erik Vandendries, MD PhD, Veronique Page, M.Sc, Uchenna Onyekwere, MD MPh, Yunyang Wang, M.Sc, M.Pharm, Joseph C. Cappelleri, PhD MPH, MS, Irina Proskorovsky, M.Sc

Blood (2017) 130 (Supplement 1): 2558.

https://doi.org/10.1182/blood.V130.Suppl_1.2558.2558

Published: 2017

Journal Articles

Matching-Adjusted Indirect Comparison of Relative Efficacies Is Feasible and Useful in the Multiple Myeloma Therapy Landscape: A Comparison of Pomalidomide Plus Low-Dose Dexamethasone Versus Daratumumab

Kejal Parikh, Irina Proskorovsky, MSc, Safiya Abouzaid, Stanimira Krotneva, MSc, Veronique Page, MSc, Christopher G Pelligra, BA, Shien Guo, PhD, Jorge L Mouro, Sikander Ailawadhi, MD

Blood (2016) 128 (22): 5946.

https://doi.org/10.1182/blood.V128.22.5946.5946

Published: 2016

Journal Articles

Determinants of Global QOL and Physical and Social Functionality In Multiple Myeloma

Karin Jordan, PhD, K. Jack Ishak, PhD, Philip Lewis, PhD, Irina Proskorovsky, MSc, Krista A Payne, M.Ed, Noreen Lordan, BSc, Charalampia Kyriakou, MD, PhD, Faith Davies, Sarah Peters, Catherine D Williams, MD

Blood (2010) 116 (21): 934.

https://doi.org/10.1182/blood.V116.21.934.934

Published: 2010

Journal Articles

Components of Global Quality of Life In Multiple Myeloma

Catherine D Williams, MD, Irina Proskorovsky, MSc, Philip Lewis, PhD, K. Jack Ishak, PhD, Krista A Payne, M.Ed, Noreen Lordan, BSc, Charalampia Kyriakou, MD, PhD, Faith Davies, MD, Sarah Peters, Karin Jordan, PhD

Blood (2010) 116 (21): 4735.

https://doi.org/10.1182/blood.V116.21.4735.4735

Published: 2010

NARROW

Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Matching-Adjusted Indirect Comparison of Relative Efficacies Is Feasible and Useful in the Multiple Myeloma Therapy Landscape: A Comparison of Pomalidomide Plus Low-Dose Dexamethasone Versus Daratumumab

Determinants of Global QOL and Physical and Social Functionality In Multiple Myeloma

Components of Global Quality of Life In Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Matching-Adjusted Indirect Comparison of Relative Efficacies Is Feasible and Useful in the Multiple Myeloma Therapy Landscape: A Comparison of Pomalidomide Plus Low-Dose Dexamethasone Versus Daratumumab

Determinants of Global QOL and Physical and Social Functionality In Multiple Myeloma

Components of Global Quality of Life In Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only